Drug Profile
AVI 5126
Alternative Names: AVI-5126; GTX 5126; Restin-CPLatest Information Update: 27 Jul 2010
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Developer AVI BioPharma; Global Therapeutics
- Class Vascular disorder therapies
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis
Most Recent Events
- 01 Jun 2010 Discontinued - Phase-II for Coronary artery restenosis in Germany (Intracoronary)
- 01 Jun 2010 Cook terminates a phase II trial [NCT00777842] in Coronary artery restenosis in Germany
- 11 Nov 2008 Phase II clinical trials in Coronary artery restenosis in Germany (Intracoronary)